Tenaya Therapeutics Stock Today
| TNYA Stock | USD 2.04 0.11 5.12% |
Performance0 of 100
| Odds Of DistressLess than 38
|
Tenaya Therapeutics is trading at 2.04 as of the 19th of October 2024, a 5.12 percent decrease since the beginning of the trading day. The stock's open price was 2.15. Tenaya Therapeutics has about a 38 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Equity ratings for Tenaya Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 19th of September 2024 and ending today, the 19th of October 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 30th of July 2021 | Category Healthcare | Classification Health Care |
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. The company was incorporated in 2016 and is headquartered in South San Francisco, California. Tenaya Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 78.89 M outstanding shares of which 5.08 M shares are at this time shorted by private and institutional investors with about 12.39 trading days to cover. More on Tenaya Therapeutics
Moving together with Tenaya Stock
| 0.76 | VALN | Valneva SE ADR | PairCorr |
| 0.85 | DYAI | Dyadic International | PairCorr |
| 0.86 | ERNA | Eterna Therapeutics | PairCorr |
| 0.74 | DNA | Ginkgo Bioworks Holdings | PairCorr |
Moving against Tenaya Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Tenaya Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Secretary CEO | Faraz MBA | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsTenaya Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Tenaya Therapeutics' financial leverage. It provides some insight into what part of Tenaya Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Tenaya Therapeutics (TNYA) is traded on NASDAQ Exchange in USA. It is located in 171 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 and employs 140 people. Tenaya Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 208.38 M. Tenaya Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 78.89 M outstanding shares of which 5.08 M shares are at this time shorted by private and institutional investors with about 12.39 trading days to cover.
Tenaya Therapeutics currently holds about 180.92 M in cash with (102.07 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.37, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Tenaya Therapeutics Probability Of Bankruptcy
Ownership AllocationTenaya Therapeutics shows a total of 78.89 Million outstanding shares. The majority of Tenaya Therapeutics outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Tenaya Therapeutics to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Tenaya Therapeutics. Please pay attention to any change in the institutional holdings of Tenaya Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Tenaya Ownership Details
Tenaya Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Fmr Inc | 2024-06-30 | 1.3 M | |
| Geode Capital Management, Llc | 2024-06-30 | 1.2 M | |
| State Street Corp | 2024-06-30 | 1 M | |
| Euclidean Capital Llc | 2024-06-30 | 1 M | |
| Adage Capital Partners Gp Llc | 2024-06-30 | 1000 K | |
| Alphabet Inc | 2024-06-30 | 915.7 K | |
| Stepstone Group Llc | 2024-06-30 | 462.2 K | |
| Northern Trust Corp | 2024-06-30 | 394 K | |
| Schonfeld Strategic Advisors Llc | 2024-06-30 | 357.5 K | |
| Column Group Llc | 2024-06-30 | 9.4 M | |
| Ra Capital Management, Llc | 2024-06-30 | 7.6 M |
Tenaya Therapeutics Historical Income Statement
Tenaya Stock Against Markets
Tenaya Therapeutics Corporate Management
| Deepak MD | Chairman Founder | Profile | |
| Saptarsi MD | Scientific Founder | Profile | |
| Sheng Ding | Scientific Founder | Profile | |
| Benoit Bruneau | Scientific Founder | Profile | |
| Timothy Hoey | Chief Officer | Profile | |
| Leone MBA | Chief Officer | Profile | |
| Chihiro Saito | Senior Officer | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tenaya Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. For information on how to trade Tenaya Stock refer to our How to Trade Tenaya Stock guide.You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tenaya Therapeutics. If investors know Tenaya will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tenaya Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.53) | Return On Assets (0.41) | Return On Equity (0.75) |
The market value of Tenaya Therapeutics is measured differently than its book value, which is the value of Tenaya that is recorded on the company's balance sheet. Investors also form their own opinion of Tenaya Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Tenaya Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tenaya Therapeutics' market value can be influenced by many factors that don't directly affect Tenaya Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tenaya Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tenaya Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tenaya Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.